Protalix BioTherapeutics (PLX) Profit After Tax (QoQ) (2010 - 2026)
Protalix BioTherapeutics (PLX) Profit After Tax (QoQ) (2010 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Protalix BioTherapeutics | 189.97 Mn | 149.31 Mn | 12.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -79.38% |
| Mar 31, 2026 | 432.79% |
| Dec 31, 2025 | -333.72% |
| Sep 30, 2025 | 1,335.98% |
| Jun 30, 2025 | 104.53% |
| Mar 31, 2025 | -155.73% |
| Dec 31, 2024 | 100.68% |
| Sep 30, 2024 | 246.89% |
| Jun 30, 2024 | 52.06% |
| Mar 31, 2024 | 23.97% |
| Dec 31, 2023 | -226.35% |
| Sep 30, 2023 | -109.58% |
| Jun 30, 2023 | 717.66% |
| Mar 31, 2023 | 16.28% |
| Dec 31, 2022 | -4.85% |
| Sep 30, 2022 | 33.13% |
| Jun 30, 2022 | -133.33% |
| Mar 31, 2022 | 65.71% |
| Dec 31, 2021 | -58.78% |
| Sep 30, 2021 | 62.65% |